1.55
-0.06(-3.73%)
Currency In USD
| Previous Close | 1.61 |
| Open | 1.59 |
| Day High | 1.63 |
| Day Low | 1.55 |
| 52-Week High | 3.07 |
| 52-Week Low | 0.46 |
| Volume | 1.9M |
| Average Volume | 4.25M |
| Market Cap | 205.73M |
| PE | -3.44 |
| EPS | -0.45 |
| Moving Average 50 Days | 2.22 |
| Moving Average 200 Days | 1.42 |
| Change | -0.06 |
If you invested $1000 in Invivyd, Inc. (IVVD) since IPO date, it would be worth $74.23 as of February 21, 2026 at a share price of $1.55. Whereas If you bought $1000 worth of Invivyd, Inc. (IVVD) shares 3 years ago, it would be worth $815.79 as of February 21, 2026 at a share price of $1.55.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration
GlobeNewswire Inc.
Feb 03, 2026 12:01 PM GMT
LIBERTY is part of the Company’s broader REVOLUTION clinical program designed to elaborate the profile of monoclonal antibody-mediated prophylaxis from COVID-19 and the potential medical benefits to vulnerable AmericansThe LIBERTY clinical trial will
Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention
GlobeNewswire Inc.
Jan 22, 2026 12:01 PM GMT
World champion skier Lindsey Vonn Invivyd announces partnership with world champion skier Lindsey Vonn to educate Americans on antibodies and disease prevention The educational campaign will focus on teaching the American public about antibodies
Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026
GlobeNewswire Inc.
Jan 20, 2026 12:01 PM GMT
Phase 2 clinical trial will evaluate the safety, translational biology, and exploratory clinical efficacy of VYD2311 in people with Long COVID or COVID vaccine injuryParticipants to include people with Long COVID who demonstrate evidence of chronic i